Benzinga | Dec 17, 2021 04:41AM EST

SVB Leerink Maintains Outperform on Zentalis Pharmaceuticals, Raises Price Target to $97

SVB Leerink analyst Andrew Berens maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform and raises the price target from $89 to $97.